Related Experiment Video
Updated: May 19, 2026
08:53
Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery
Published on: April 16, 2019
Single siRNA nanocapsules for enhanced RNAi delivery
Ming Yan1, Min Liang, Jing Wen
1Department of Microbiology, Immunology, and Molecular Genetics, and California NanoSystems Institute (CNSI), University of California, Los Angeles, California 90095, USA.
Journal of the American Chemical Society
|August 8, 2012
Summary
This study introduces a novel nanocapsule for delivering single small interfering RNA (siRNA) molecules, enhancing stability and cellular uptake for potential therapeutic applications in treating diseases.
Area of Science:
- Biotechnology
- Nanotechnology
- Molecular Biology
Background:
- Synthetic small interfering RNA (siRNA) shows therapeutic promise but faces challenges in stability and delivery.
- Effective delivery of RNA interference (RNAi) compounds to target tissues and cells remains a significant hurdle for clinical translation.
Purpose of the Study:
- To develop and validate a novel nanocapsule-based delivery system for single siRNA molecules.
- To demonstrate the efficacy of this system in downregulating specific gene targets, using CCR5 as a model for HIV therapy.
Main Methods:
- Encapsulation of single siRNA molecules within degradable polymer nanocapsules (approx. 20 nm diameter, positive surface charge).
- Delivery of CCR5-siRNA nanocapsules into 293T cells to assess CCR5 RNA downregulation.
- Evaluation of nanocapsule stability and siRNA integrity in the presence of RNase and human serum.
- Comparison of gene silencing efficiency with free siRNA and lipofectamine-mediated delivery.
Main Results:
- Nanocapsules successfully delivered CCR5-siRNA, downregulating CCR5 RNA expression to 8% in 293T cells.
- Nanocapsules protected siRNA from degradation by RNase and serum, maintaining integrity for 1 hour.
- In serum, nanocapsule-delivered siRNA achieved <15% CCR5-mCherry expression, significantly outperforming lipofectamine (55%).
Conclusions:
- A novel single siRNA nanocapsule delivery platform has been developed.
- This technology offers enhanced stability and effective gene silencing, addressing key limitations of current siRNA therapeutics.
- The nanocapsule platform holds potential for therapeutic development in various human diseases.
Related Concept Videos
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
02:30Small interfering RNAs (siRNA)
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...